Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening.
about
Impact of epithelial ovarian cancer screening on patient-relevant outcomes in average-risk postmenopausal womenCharacterization of the low molecular weight human serum proteome.Screening serum hepatocellular carcinoma-associated proteins by SELDI-based protein spectrum analysisThe identification of unique serum proteins of HIV-1 latently infected long-term non-progressor patients.Searching for Potential Ovarian Cancer Biomarkers with Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry.Detection of autoantibodies to multiple tumor-associated antigens in the immunodiagnosis of ovarian cancer.Identification of serum biomarkers for ovarian cancer using MALDI-TOF-MS combined with magnetic beads.Inhibin at 90: from discovery to clinical application, a historical reviewBeyond malignancy: the role of carbohydrate antigen 125 in heart failure.Promising directions for the diagnosis and management of gynecological cancers.The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.Multicolor in vivo targeted imaging to guide real-time surgery of HER2-positive micrometastases in a two-tumor coincident model of ovarian cancer.Methodology and applications of disease biomarker identification in human serum.Tumour biomarkers in heart failure: is there a role for CA-125?Development of a selected reaction monitoring mass spectrometry-based assay to detect asparaginyl endopeptidase activity in biological fluidsDifferences in the Molecular Species of CA125 Across the Phases of the Menstrual Cycle.Meta-analysis of green tea drinking and the prevalence of gynecological tumors in women.PPARγ Modulation of Cytokine-Stimulated MUC16 (CA125) Expression in Breast and Ovarian Cancer-Derived Cells.Expanded metabolomics approach to profiling endogenous carbohydrates in the serum of ovarian cancer patients.The Efficacy of Radiofrequency Hyperthermia Combined with Chemotherapy in the Treatment of Advanced Ovarian Cancer.Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma
P2860
Q24195062-03A13794-8E59-4094-B145-D45F1B3287EFQ31153810-6036FFEA-188C-424C-9414-6CB9EF04B0F6Q33321107-0D0328A7-EE89-46A6-8E53-C5AE46E10351Q33626049-447B4848-C13E-47A8-9B68-91B94323AB45Q33642806-585539BA-20A2-467A-8103-4D43C674D1F1Q33890172-0AF3416E-001A-475F-90A0-9A28501A5DF5Q33921490-35CE4ED2-DCB5-44B1-BB2C-A96770552E48Q34204531-441CB72B-80AD-48EE-BFAB-C7B0A8FF37F2Q34255880-4AF97E50-FD43-473E-BD1B-7D41D8261E7CQ35648859-30C9B06D-48AE-49FC-BAB9-219FE6FA0AB3Q37096960-2BC1A7C9-BD6D-43F9-B7E8-AFDF59F332B5Q37329697-B4E83F6A-4849-4BD6-A6FE-D5A978F08E09Q37574961-0A340CF0-3443-4D5D-AB52-4729C67A42F0Q37869633-86749F2B-6041-4359-9D54-76E96F919DFAQ38816612-5AEA14F5-8416-496B-ACD6-FE0AEE4BC446Q39063141-69EEF3E6-BF70-49C8-9FE6-898C22919FCBQ50476830-0A217D0E-404D-4D6B-BD46-3EEADB1462DEQ51706809-8B592D27-2388-43B8-AE1F-7A8A17235163Q53290783-F9BCFF86-83E4-4D70-B385-70B9510CA37BQ55338071-F51D8172-882C-481B-B430-BBD2DF5F3ADFQ57941761-586BE70D-7404-473D-8559-57DCDD7F92AB
P2860
Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Current status of the molecula ...... its use in clinical screening.
@ast
Current status of the molecula ...... its use in clinical screening.
@en
type
label
Current status of the molecula ...... its use in clinical screening.
@ast
Current status of the molecula ...... its use in clinical screening.
@en
prefLabel
Current status of the molecula ...... its use in clinical screening.
@ast
Current status of the molecula ...... its use in clinical screening.
@en
P356
P1433
P1476
Current status of the molecula ...... its use in clinical screening.
@en
P2093
Caroline Whitehouse
Ellen Solomon
P304
P356
10.1006/GYNO.2002.6708
P407
P433
P577
2003-01-01T00:00:00Z